Mammalian Transient Protein Expression Market

2020 Analysis and Review: Mammalian Transient Protein Expression Market by Application – Bio Production and Academic Research for 2020-2030

About the Report

The use of mammalian transient protein expression in quick production of proteins continues to spur developments. The capability of mammalian cells to aid development of proteins with similar bioactivity as natural proteins continues to boost their adoption. In this expansive new study, Future Market Insights analyzes the commercial prospects of mammalian transient protein expression market, analyzing key developments across a range of products and end-uses. The report tracks market growth since 2013, offering historical analysis for 2013-2019, while offering forecast for 2020-2030 with a detailed assessment of the COVID-19 impact.

Introduction

The mammalian transient protein expression market has reflected steady growth on the back of growing demand from the biomedicine sector. Efforts into vaccine development continue to create possibilities for new opportunities.

A recent market study by Future Market Insights on the mammalian transient protein expression market opines that the market will reach US$ 540 Mn valuation in 2020.

In recent years, the mammalian transient protein expression market has displayed strong growth with rising interest in terms of academics and researchers in the bio-medicine sector. These factors influence market developments through the forecast period.

Advancements in Genetic Research Creates Opportunities

Innovations in the field of genetic research have played a key role in the development mammalian transient protein expression as an efficient process. Research on the characteristics of animal cells has gained increasing importance in the zoology domain. Academic applications on genetic mutations in animals will further lead to gains in this discipline.

Market players are leveraging the growing investments into the field of genetic research and have displayed interest towards cultures of animal cells, in addition to the development of therapeutic proteins. Studies on genetic expression for plants and animals, and methods used for genetic expression in progeny continue to aid development.

Recombinant Protein Therapeutic Applications Drive Demand

Protein-based therapeutics have becoming increasingly mainstream in the pharmaceutical sector. Mammalian cells have become highly sought-after as a standard host for the development and production of therapeutic proteins, driven by post-translational folding and modifications.

Industrial laboratories have extensively invested in the development of stable cell lines for gene coding recombinant proteins in genomes. Currently, a major challenge in the development process is the massive time requirement for the isolation of high-production, stable CHO (Chinese Hamster Ovary) cell lines.

Rapid assessment of candidate r-proteins in studies leading to the development of stable cell lines is a popular solution in the industry. Transient gene expression processes are ideal for such purposes, owing to the high potential for the generation of therapeutic r-proteins within with minimal time frames. This factor is likely to have significant influence on market development.

Automation Gains Importance in Large-scale Protein Expression

Challenges associated with large-scale mammalian cell-based expression systems as an avenue for the development and production of targets in terms of insect cell expression and heterologous prokaryotic hosts are an issue for market players.

In mammalian expression systems, protein complexes, can be expressed according to native cell type, under physiological conditions. This is largely dependent on varying molecular systems working together for efficient quality control and production processes. However, large-scale expression of eukaryotic proteins in a soluble, stable forms is still an obstacle.

As a result, automated mammalian cell lines incorporating stable transfected cell lines has become mainstream in the processes of drug discovery. Automation is costlier to market players than manual alternatives owing to set up costs and consumables.

However, benefits in terms of time saved and the higher productivity mitigates these issues. A key advantage of automated systems is the reproducibility of expression and minimal risk from human error.

Key Challenges

With substantial interest by contract research organizations, the adoption of mammalian transient protein expression has gone up in the field of biotechnology on a global scale.

Market players are also likely to face growing challenges during the assessment period. Poor purification results in sub-optimal conditions is a major operational challenge.

Also, adjustments in terms of supernatant dialysis and poor media to resin ratios are issues, which has made measures such as strip-resistant nickel resins critical. Such issues require additional time and effort, which will limit market prospects through the forecast period.

Region-wise Analysis

North America Mammalian Transient Protein Expression Market

North America is the predominant market for mammalian transient protein expression accounting for more than US$ 194 million in 2020.

Relatively better access to advanced healthcare technology, and stringent healthcare regulations, and improvements to patient care are key factors that have positively impacted the market.

The use of protein expression for the development of easily available, affordable treatment options in terms of chronic disease has been a major driver. Also, the region is home to many market players, and the resultant investments into research and development has bolstered the prospects for market growth.

Led by the United States, biopharmaceutical offerings are being developed in a set of expression systems. Also, the US is home to leading research and academic centers and biotech hubs with global influence. Also, government initiatives towards cell-free protein expression and the demand for high-volume screening for protein and enzyme engineering will aid the market.

Request a sample specific to North America market

Europe Mammalian Transient Protein Expression Market

Europe is the second largest market for mammalian transient protein expression. The presence of numerous market players has been a key driving factor. Key investments into healthcare infrastructure and increased focus into genomics research is a major market driver.

Countries such as Germany, France, UK, and Switzerland has reflected increased applications in the field of proteomics. Also, the region is displaying positive prospects for biologics, owing to innovations in diabetes treatments. These trends are likely to drive market growth across major European countries for the foreseeable future.

Request a sample specific to Europe market

East Asia Mammalian Transient Protein Expression Market

East Asia is a quickly growing regional market for mammalian transient protein expression. Major investments being made towards the modernization of healthcare infrastructure and vast patient pool are key market drivers.

Led by China, the East Asia has been displaying a strong and widespread presence of contract research organizations. Access to a massive genome pool, relaxed regulations in terms of biologics, and access to adequately skilled manpower are major factors that are positively influencing growth rates within the sector.

Category-wise Insights

Reagents and Consumables Reflect Higher Demand

Key product types include instruments, expression vectors, reagents & consumables, and cell lines. Reagents & consumables account for more than 33% of the market share, and are likely to grow at high CAGR through 2030.

The requirements for replenishing supplies of consumables and reagents and the essential nature of these products in protein expression activities are the key factor driving long-term growth in the industry. 

Bio Production Applications Drive Growth

In terms of application, mammalian transient protein expression can be classified into bio production, functional cell-based assays, academic research, and others. Of these, bio production applications will drive revenue generation in the near future, at a valuation of more than US$ 224 million in 2020.

Bio production activities can be further classified into therapeutic protein production and antibody production. The demand for therapeutic protein production will remain higher, and is estimated to reach close to 60% of the market share by the end of the assessment period.

Biopharmaceutical Companies are Leading End Users

Mammalian transient protein expression can be largely classified on the basis of end users into contract research organizations, biopharmaceutical companies, and academic & research institutes. Biopharmaceutical companies will hold leading market share through the forecast period. The segment accounts for over US$ 246 Mn in 2020.

The demand from biopharmaceutical companies for the entire forecast period has largely been attributed to drug development and research activities, which will drive market developments for the foreseeable future.

Competitive Landscape

Leading players in the fragmented mammalian transient protein expressions market have been observed increasingly focusing on the launch of new product offerings including gene coding and antibody production. Strategic agreements in terms of licensing and distribution, and geographical expansion are also gaining importance.

For instance, in May 2019, ATUM announced the exclusive licensing deal with Medicago for GeneGPS, the company’s gene-coding algorithm. The product is used in the optimization of protein expression, with the aid of empirical measurements, design of experiments, and machine learning to predict gene sequences.

The company also, announced its patent for the growing scope of Leap-In, the company's transposon-based tool. The patent includes configurations of vectors associated elements in combination with transposons for the optimization of recombinant protein expression in mammalian cells.

ProteoGenix announced the development and launch of XtenCHO, a transient expression system and an optimized transfection protocol. The product is aimed towards the development and production of varied types of antibodies at substantially lower costs than the average.

Absolute Antibody Ltd. in March 2020 announced the launch of FleXpress, a high-throughput recombinant antibody production service. The operations of the service take place in an ISO-certified antibody production facility in Northeast England. The service aims towards early-stage pharma sector researchers, and reagent companies seeking to transition towards recombinant production.

These are some of the developments are will positively influence the mammalian transient protein expression industry throughout the assessment period.

Aside from these market players, other leading companies in the market include:

  • Thermo Fisher Scientific Inc.
  • Merck KgaA
  • Lonza Group
  • Agilent Technologies Inc.
  • Takara Bio Inc
  • Mirus Bio LLC
  • Bio-Rad Laboratories Inc.
  • Qiagen N.V.
  • HiMedia Laboratories
  • Promega Corporation
  • Sino Biological Inc.

The list is only indicative – full list of mammalian transient protein expressions market key players is available upon request.

Mammalian Transient Protein Expression Market Report: Scope

Attribute

Details

Forecast Period

2020-2030

Historical Data Available for

2015-2019

Market Analysis

US$ Million for value

Key Regions Covered

North America, Latin America, Europe, East Asia, South Asia, Oceania, and Middle East & Africa (MEA)

Key Countries Covered

US, Canada, Brazil, Mexico, Argentina, Germany, Switzerland, U.K., France, Italy, Spain, BENELUX, Russia, China, Japan, South Korea, India, Indonesia, Malaysia, Thailand, Australia, New Zealand, GCC Countries, Turkey, South Africa

Key Segments Covered

Product Type, Application, End User, and Region

Key Companies Profiled

Thermo Fisher Scientific, Merck KgaA, Lonza, Agilent Technologies Inc., Takara Bio Inc., Mirus Bio Inc., Bio-Rad Laboratories Inc., Qiagen N.V.,HiMedia Laboratories, Promega Corporation, Sino Biological Inc.(only indicative list)

Report Coverage

Market Forecast, brand share analysis, competition intelligence, DROT analysis, Market Dynamics and Challenges, Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Key Questions Answered by the Report

  • What is the size of the mammalian transient protein expressions market?

    The global mammalian transient protein expressions market is estimated to reach a valuation of approximately US$ 540 million in 2020.

  • Which is the largest market for mammalian transient protein expressions?

    The US is likely to remain the largest market for mammalian transient protein expression products during the assessment period, owing to adoption in academic centers and research organizations.

  • Which are the top companies in global mammalian transient protein expressions market?

    Thermo Fisher Scientific, Merck KgaA, Lonza, Agilent Technologies Inc., Takara Bio Inc., Mirus Bio Inc., Bio-Rad Laboratories Inc., Qiagen N.V., are some of the leading players in the mammalian transient protein expressions market.

  • What are the applications of mammalian transient protein expressions?

    Mammalian transient protein expression services largely play roles in the bio-medicine sector to develop and produce a wide range of antibodies and therapeutic protein products.

  • What are the prospects for the mammalian transient protein expressions market in Asia?

    Countries in the South Asia region are displaying relatively faster growth than other markets supported by increasingly robust retail channels, despite the cast potential for regional penetration by market leaders.

  • What is the near-term competitive outlook of the global mammalian transient protein expressions market?

    The global mammalian transient protein expressions market is largely fragmented, with product launches and development, in addition to geographic expansion gaining ground.

Enquiry before Buying

  • Is this research conducted by Future Market Insights?

    Yes, the research has been conducted by expert analysts of Future Market Insights through a combination of primary research and secondary research. To know more about how the research was conducted, you can speak to research analyst.

  • What research methodology is followed by FMI?

    FMI follows a methodology that encompasses demand side assessment of the market, and triangulates the same through supply side analysis. This methodology is based on use of standard market structure, methods and definitions.

  • Who are the respondents for primary research?

    FMI speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, industry experts. For a full list of primary respondents, please reach out to us.

  • What are the sources of secondary research?

    FMI conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request

  • Is a sample of this report available for evaluation?

    Yes, you can request a sample and it will be sent to you through an email.

  • How can I buy this report?

    FMI provides a secure online payment system to buy report seamlessly. You can buy the report securely and safely.

Key Segments

Product Type

  • Instruments
  • Expression Vector
  • Reagents & Consumables
  • Cell Lines
    • Chinese Hamster Ovary Cells
    • Human Embryonic Kidney Cells
    • Others

Application

  • Bio Production
    • Antibody Production
    • Therapeutic Protein Production
  • Functional Cell Based Assays
  • Academic Research
  • Others

End User

  • Contract Research Organization
  • Biopharmaceutical Companies
  • Academic & Research Institutes

Region

  • North America (U.S., Canada)
  • Latin America (Brazil, Mexico, Argentina, and Rest of Latin America)
  • Europe (Germany, Switzerland, France, UK, Rest of Europe)
  • East Asia (China, Japan, South Korea)
  • South Asia (India, Thailand, Indonesia, Malaysia, Rest of South Asia)
  • Oceania (Australia and New Zealand)
  • Middle East & Africa (GCC Countries, Turkey, South Africa, Rest of MEA)

Need specific information?

In the news

How Businesses Can Utilize Market Research to Create Reactive, Recession-proof Strategies for Survival

by - Sudip Saha, Managing Director and Co-Founder of Future Market Insights

Our Clients

View Our Reports from Healthcare

View Reports

Recommendations

Mammalian Transient Protein Expression Market